Copyright
©The Author(s) 2024.
World J Cardiol. Aug 26, 2024; 16(8): 469-483
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469
Table 3 Baseline characteristics of randomized clinical trials included in the meta-analysis of bone-marrow-derived mesenchymal-stem-cell-based cardiac therapy, n (%)
Ulus et al[25], 2020 (Türkiye) | Rodrigo et al[32], 2013 (Netherlands) | Kim et al[16], 2018 (South Korea) | Bolli et al[23], 2020 (USA) | ||
Study type | Open-label RCT | RCT | RCT | RCT | |
Phase | I/II | I/II | I | I | |
Condition | CIC | MI | MI | HF | |
Sample size | Total | 28 | 54 | 26 | 31 |
Intervention (male) | 12 (100) | 9 (78) | 14 (100) | 14 (43) | |
Control (male) | 16 (100) | 45 (78) | 12 (100) | 17 (24) | |
Mean age (mean ± SD) | Intervention | 56.9 ± 5.20 | 56 ± 8 | 55.3 ± 8.6 | 54.7 ± 12.8 |
Control | 65.3 ± 6.8 | 61 ± 11 | 57.8 ± 8.9 | 58.2 ± 11.2 | |
Mean BMI (mean ± SD) | Intervention | 26.2 ± 3.12 | N/A | N/A | 30.2 ± 9.0 |
Control | 26.6 ± 4.8 | N/A | N/A | 30.4 ± 6.5 | |
Number of smokers | Intervention | 11 (91.6) | 6 (67) | 5 (35.7) | 5 (36) |
Control | 15 (88.2) | 19 (42) | 5 (41.7) | 3 (18) | |
HTN | Intervention | 6 (50) | 4 (44) | 5 (35.7) | 6 (43) |
Control | 11 (64.7) | 18 (40) | 5 (41.7) | 10 (59) | |
DM | Intervention | 4 (33.3) | 1 (11) | 3 (21.4) | 3 (21) |
Control | 9 (52.9) | 5 (11) | 2 (16.7) | 5 (29) | |
NYHA; I (n), II (n), III (n), IV (n) | Intervention | 2.2 ± 0.6 | N/A | N/A | II (13), III (1) |
Control | 2.1 ± 0.37 | N/A | N/A | II (13), III (4) | |
Comparison | CABG only | No placebo (optimal MI treatment) | No placebo (optimal MI treatment) | HF treatments | |
Follow-up duration | 1, 3, 6, and 12 mo | 3, 6, 12 mo, 4, 5 years | 4 and 12 mo | 6 and 12 mo | |
Assessment modality (Yes/no) | ECG | Yes | Yes - Holter | No | Yes |
Echo | Yes | Yes | Yes | No | |
MRI | Yes | No | No | Yes - CMR | |
Cardiac CT | No | No | No | No | |
SPECT | Yes | Yes | Yes | No | |
Measured outcomes | LVEF, LV remodeling, myocardial mass, 6MWD, NYHA score | Safety and feasibility of IM delivery after PCI for MI (primary). Efficacy regarding change in infarct size, LVEF, LVEDV, and LVESV (secondary) | Absolute changes in global LVEF from baseline to 4 months after PCI using SPECT, Echo changes in global LVEF at 12 mo (primary). Changes in LVEDV, LVESV, and MACE (secondary) | Safety and feasibility of allogenic MSC in population (primary). Effects of allogenic MSC on LV function (LVEF, LVEDV, LVESV, scar), morphology, and functional status (6MWD, MLHFQ) (secondary) |
- Citation: Safwan M, Bourgleh MS, Aldoush M, Haider KH. Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis. World J Cardiol 2024; 16(8): 469-483
- URL: https://www.wjgnet.com/1949-8462/full/v16/i8/469.htm
- DOI: https://dx.doi.org/10.4330/wjc.v16.i8.469